Zhonghui Bio-B: Quadrivalent influenza vaccine Huierkangxin has been shortlisted for the initial review of the National Medical Insurance Innovation Catalogue.

Quadrivalent influenza vaccine Huierkangxin has been shortlisted for the initial review of the National Medical Insurance Innovation Catalogue.

August 13, 2025 Source: drugdu 89

Zhongzheng Smart Finance News: Zhuhai Zhuhui Biological - B (02627) announced in the morning of August 13 that according to the announcement of the National Healthcare Security Administration on August 12, the company's quadrivalent influenza virus subunit vaccine, Huier Kangxin, has been included in the preliminary review list of innovative drugs for commercial health insurance in the country this year. It is the only vaccine product on the list.

This vaccine was approved for marketing by the National Medical Products Administration in May 2023 and is suitable for people aged three and above (with a hemagglutinin concentration of 15μg/0.5ml for the virus strain). It is the first and only quadrivalent influenza virus subunit vaccine in China, providing broad protection against influenza viruses of type A H1N1, H3N2 and type B Yamagata and Victoria. The product is an optimized and upgraded version of traditional split vaccines, featuring comprehensive protection, high antigen purity and low risk of adverse reactions.

The company reminds that it cannot guarantee the ultimate successful development and promotion to all the expected age groups.

https://finance.eastmoney.com/a/202508133482768960.html

By editor

Quadrivalent influenza vaccine Huierkangxin has been shortlisted for the initial review of the National Medical Insurance Innovation Catalogue.

Read more on

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us